Folate-appended CDs in cancer therapy
The team of Motoyama in Kumamoto has recently published new results on folate-appended CDs in leukemia and ovarian cancer (1,2).
Tag: Cancer therapy
Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation
A patent application by Knut M. Wittkowski (ASDERA LLC, US) entitled “Use of cyclodextrins in diseases and disorders involving phospholipid
A Novel Folic Acid Receptor-Targeted Drug Delivery System Based on Curcumin-Loaded β-Cyclodextrin Nanoparticles for Cancer Treatment
A novel folate receptor-targeted β-cyclodextrin drug delivery vehicle was constructed to improve the bioavailability, biosafety, and drug loading capacity of
Hyperbranched polymers functionalized β-cyclodextrin
Wan et al. (2021) published on the synthesis and potential utilization of β-CD modified with hyperbranced polyglycerol polymer and decorated
Antibacterial and Cytotoxic Effects of Cyclodextrin-Triazole-Titanium Based Nanocomposite
The antibacterial activity of triazole functionalized cyclodextrin (CD.Click) and cyclodextrin-triazole-titanium based nanocomposite (CD.COM) was evaluated. The results indicated that CD.Click
Clinical Application of Cytokines in Cancer Immunotherapy
Cytokines are key components of the immune system and play pivotal roles in anticancer immune response. Cytokines as either therapeutic
Regorafenib@mannose-γ-cyclodextrin channel-type nanoparticles for colorectal cancer therapy
The malignancy of colorectal cancer is connected with inflammation and tumor-associated macrophages (TAMs), but effective therapeutics for colorectal cancer are
Multicharge beta-cyclodextrin supramolecular assembly for ATP capture and drug release
Water-soluble seven hexylimidazolium modified amphiphilic cyclodextrin (AMCD) selectively combined with ATP to form a stable 1 : 1 inclusion complex
4th China International BioPharma Conference & Exhibition
2021 China International BioPharma Conference will be held on September 19th-21th in China Medical City Convention and Exhibition Center, Taizhou China.
Top-line final data from CD-enabled Cantrixil Phase I study confirms prior positive efficacy and safety signals
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company shared top-line final data from its phase I study of Cantrixil (TRX-E-002-1)